PURPOSE: Studies of smoking and risk of non-Hodgkin lymphoma (NHL) have yielded inconsistent results, possibly due to subtype heterogeneity and/or genetic variation impacting the metabolism of tobacco-derived carcinogens, including substrates of the N-acetyltransferase enzymes NAT1 and NAT2. METHODS: We conducted a pooled analysis of 5,026 NHL cases and 4,630 controls from seven case-control studies in the international lymphoma epidemiology consortium to examine associations between smoking, variation in the N-acetyltransferase genes NAT1 and NAT2, and risk of NHL subtypes. Smoking data were harmonized across studies, and genetic variants in NAT1 and NAT2 were used to infer acetylation phenotype of the NAT1 and NAT2 enzymes, respectively. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for risk of NHL and subtypes were calculated using joint fixed effects unconditional logistic regression models. RESULTS: Current smoking was associated with a significant 30 % increased risk of follicular lymphoma (n = 1,176) but not NHL overall or other NHL subtypes. The association was similar among NAT2 slow (OR 1.36; 95 % CI 1.07-1.75) and intermediate/rapid (OR 1.27; 95 % CI 0.95-1.69) acetylators (p (interaction) = 0.82) and also did not differ by NAT1*10 allelotype. Neither NAT2 phenotype nor NAT1*10 allelotype was associated with risk of NHL overall or NHL subtypes. CONCLUSION: The current findings provide further evidence for a modest association between current smoking and follicular lymphoma risk and suggest that this association may not be influenced by variation in the N-acetyltransferase enzymes.
PURPOSE: Studies of smoking and risk of non-Hodgkin lymphoma (NHL) have yielded inconsistent results, possibly due to subtype heterogeneity and/or genetic variation impacting the metabolism of tobacco-derived carcinogens, including substrates of the N-acetyltransferase enzymes NAT1 and NAT2. METHODS: We conducted a pooled analysis of 5,026 NHL cases and 4,630 controls from seven case-control studies in the international lymphoma epidemiology consortium to examine associations between smoking, variation in the N-acetyltransferase genes NAT1 and NAT2, and risk of NHL subtypes. Smoking data were harmonized across studies, and genetic variants in NAT1 and NAT2 were used to infer acetylation phenotype of the NAT1 and NAT2 enzymes, respectively. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for risk of NHL and subtypes were calculated using joint fixed effects unconditional logistic regression models. RESULTS: Current smoking was associated with a significant 30 % increased risk of follicular lymphoma (n = 1,176) but not NHL overall or other NHL subtypes. The association was similar among NAT2 slow (OR 1.36; 95 % CI 1.07-1.75) and intermediate/rapid (OR 1.27; 95 % CI 0.95-1.69) acetylators (p (interaction) = 0.82) and also did not differ by NAT1*10 allelotype. Neither NAT2 phenotype nor NAT1*10 allelotype was associated with risk of NHL overall or NHL subtypes. CONCLUSION: The current findings provide further evidence for a modest association between current smoking and follicular lymphoma risk and suggest that this association may not be influenced by variation in the N-acetyltransferase enzymes.
Authors: D W Hein; M A Doll; A J Fretland; M A Leff; S J Webb; G H Xiao; U S Devanaboyina; N A Nangju; Y Feng Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-01 Impact factor: 4.254
Authors: Silvia de Sanjosé; Yolanda Benavente; Alexandra Nieters; Lenka Foretova; Marc Maynadié; Pier Luigi Cocco; Anthony Staines; Martine Vornanen; Paolo Boffetta; Nikolaus Becker; Tomas Alvaro; Paul Brennan Journal: Am J Epidemiol Date: 2006-05-26 Impact factor: 4.897
Authors: Lindsay McOmber Morton; Theodore R Holford; Brian Leaderer; Yawei Zhang; Shelia Hoar Zahm; Peter Boyle; Stuart Flynn; Giovanni Tallini; Patricia H Owens; Bing Zhang; Tongzhang Zheng Journal: Cancer Causes Control Date: 2003-09 Impact factor: 2.506
Authors: Jean L Koff; Dai Chihara; Anh Phan; Loretta J Nastoupil; Jessica N Williams; Christopher R Flowers Journal: Curr Hematol Malig Rep Date: 2015-09 Impact factor: 3.952
Authors: Dai Chihara; Loretta J Nastoupil; Jessica N Williams; Paul Lee; Jean L Koff; Christopher R Flowers Journal: Expert Rev Anticancer Ther Date: 2015-04-11 Impact factor: 4.512
Authors: Susan L Slager; Yolanda Benavente; Aaron Blair; Roel Vermeulen; James R Cerhan; Adele Seniori Costantini; Alain Monnereau; Alexandra Nieters; Jacqueline Clavel; Timothy G Call; Marc Maynadié; Qing Lan; Christina A Clarke; Tracy Lightfoot; Aaron D Norman; Joshua N Sampson; Delphine Casabonne; Pierluigi Cocco; Silvia de Sanjosé Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Sophia S Wang; Christopher R Flowers; Marshall E Kadin; Ellen T Chang; Ann Maree Hughes; Stephen M Ansell; Andrew L Feldman; Tracy Lightfoot; Paolo Boffetta; Mads Melbye; Qing Lan; Joshua N Sampson; Lindsay M Morton; Yawei Zhang; Dennis D Weisenburger Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2014-08 Impact factor: 2.089
Authors: Chandra Chiappin Cardoso; Ana Carolina Rabello de Moraes; Joanita Angela Gonzaga Del Moral; Maria Claudia Santos-Silva Journal: Rev Bras Hematol Hemoter Date: 2016-03-09